Similar Clinical Improvement Rates among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression

Jurij Hanžel; Rocio Sedano; Jenny Jeyarajah; Guangyong Zou; Stefanie C. McFarlane; Christopher Ma; Vipul Jairath

doi:10.1093/ibd/izac018

Similar Clinical Improvement Rates among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression

Jurij Hanžel
, Rocio Sedano
, Jenny Jeyarajah
, Guangyong Zou
, Stefanie C. McFarlane
, Christopher Ma
, Vipul Jairath^*

^*Corresponding author for this work

University of Ljubljana
Alimentiv Inc, London, Ontario, Canada
Amsterdam UMC - University of Amsterdam
Western University
University of Calgary

Research output: Contribution to journal › Article › Academic › peer-review

6 Downloads (Pure)

Abstract

We conducted a systematic review and metaregression of pivotal Crohn’s disease trials to evaluate the rates of change in Crohn’s Disease Activity Index scores in patients receiving biologic treatments. The speed of clinical improvement was similar among biologic drug classes..

Original language	English
Pages (from-to)	1462-1464
Journal	Inflammatory bowel diseases
Volume	28
Issue number	9
DOIs	https://doi.org/10.1093/ibd/izac018
Publication status	Published - 1 Sept 2022
Externally published	Yes

Access to Document

10.1093/ibd/izac018

Similar-clinical-improvement-rates-among-biologic-drug-classes-in-crohns-disease.pdfFinal published version, 185 KBLicence: Taverne

Cite this

@article{9869005ef7924f16a6d4eef8b2ad1243,

title = "Similar Clinical Improvement Rates among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression",

abstract = "We conducted a systematic review and metaregression of pivotal Crohn{\textquoteright}s disease trials to evaluate the rates of change in Crohn{\textquoteright}s Disease Activity Index scores in patients receiving biologic treatments. The speed of clinical improvement was similar among biologic drug classes..",

author = "Jurij Han{\v z}el and Rocio Sedano and Jenny Jeyarajah and Guangyong Zou and McFarlane, \{Stefanie C.\} and Christopher Ma and Vipul Jairath",

year = "2022",

month = sep,

day = "1",

doi = "10.1093/ibd/izac018",

language = "English",

volume = "28",

pages = "1462--1464",

journal = "Inflammatory bowel diseases",

issn = "1078-0998",

publisher = "John Wiley and Sons Inc.",

number = "9",

}

TY - JOUR

T1 - Similar Clinical Improvement Rates among Biologic Drug Classes in Crohn's Disease

T2 - Systematic Review and Meta-Regression

AU - Hanžel, Jurij

AU - Sedano, Rocio

AU - Jeyarajah, Jenny

AU - Zou, Guangyong

AU - McFarlane, Stefanie C.

AU - Ma, Christopher

AU - Jairath, Vipul

PY - 2022/9/1

Y1 - 2022/9/1

N2 - We conducted a systematic review and metaregression of pivotal Crohn’s disease trials to evaluate the rates of change in Crohn’s Disease Activity Index scores in patients receiving biologic treatments. The speed of clinical improvement was similar among biologic drug classes..

AB - We conducted a systematic review and metaregression of pivotal Crohn’s disease trials to evaluate the rates of change in Crohn’s Disease Activity Index scores in patients receiving biologic treatments. The speed of clinical improvement was similar among biologic drug classes..

UR - https://www.scopus.com/pages/publications/85137138018

UR - https://www.ncbi.nlm.nih.gov/pubmed/35166778

U2 - 10.1093/ibd/izac018

DO - 10.1093/ibd/izac018

M3 - Article

C2 - 35166778

SN - 1078-0998

VL - 28

SP - 1462

EP - 1464

JO - Inflammatory bowel diseases

JF - Inflammatory bowel diseases

IS - 9

ER -

Similar Clinical Improvement Rates among Biologic Drug Classes in Crohn's Disease: Systematic Review and Meta-Regression

Abstract

Access to Document

Other files and links

Fingerprint

Cite this